NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of stem cell products, today announced evidence that its PLX-I cells have proven to be immune privileged. PLX-I cells are Pluristem’s first potential product dedicated to resolving the global shortfall of matched tissue for bone marrow transplantation by improving the engraftment of umbilical cord blood. PLX-I cells are mesenchymal stems cells obtained from the placenta and expanded by using Pluristem’s proprietary 3D PluriX™ technology.
